India: Novartis Hearing Postponed To February 30/11/2011 by Intellectual Property Watch Leave a Comment Share this:Click to share on Twitter (Opens in new window)Click to share on LinkedIn (Opens in new window)Click to share on Facebook (Opens in new window)Click to email this to a friend (Opens in new window)Click to print (Opens in new window)By Catherine Brain for Intellectual Property Watch The Supreme Court in New Delhi has postponed the Novartis v. Union of India hearing. The case will now be heard on 28 February 2012. Swiss pharmaceutical company Novartis is challenging the decision of the Intellectual Property Appellate Board, which rejected its appeal for a patent on the cancer drug, Glivec (or Gleevec). The rejection was based on section 3(d) of the Indian Patents Act 1970, which prohibits patents on new forms of known substances, unless the new form exhibits a significant enhancement in efficacy. In its 29 November postponement, the court stated that the delay is due to the over-running of another case involving the same judges. This is the third time the hearing has been rescheduled, it was initially listed for 17 January 2012. Share this:Click to share on Twitter (Opens in new window)Click to share on LinkedIn (Opens in new window)Click to share on Facebook (Opens in new window)Click to email this to a friend (Opens in new window)Click to print (Opens in new window) Related "India: Novartis Hearing Postponed To February" by Intellectual Property Watch is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.